Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-06-19
2010-12-14
Fetterolf, Brandon J (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07851443
ABSTRACT:
This invention relates to therapeutic combinations comprising VEGF Trap and a stilbene derivative, and to methods for treatment of cancer comprising administration of such combinations.
REFERENCES:
patent: 4996237 (1991-02-01), Pettit et al.
patent: 5430062 (1995-07-01), Cushman et al.
patent: 5525632 (1996-06-01), Obsumi et al.
patent: 5561122 (1996-10-01), Pettit
patent: 5674906 (1997-10-01), Hatanaka et al.
patent: 5731353 (1998-03-01), Ohsumi et al.
patent: 6933320 (2005-08-01), Bissery
patent: 2005/0032699 (2005-02-01), Holash et al.
patent: WO 00/75319 (2000-12-01), None
patent: WO 03/035008 (2003-05-01), None
patent: WO2005/000895 (2005-01-01), None
patent: WO 2005000895 (2005-01-01), None
patent: WO 2005027972 (2005-03-01), None
Holash et al. (PNAS 2002; 99: 11393-11398).
Hori et al. (British Journal of Cancer; 2002; 86: 1604-1614).
Wiesenthal (http://weisenthal.org/feedback.html, Feb. 4, 2002.
Tallarida (Drug Synergism and Dose-effect Analysis, Chapman & Hall/CRC, Boca Raton, 2000, pp. 1-13).
Berenbaum (“Synergy, additivism and antagonism in immunosuppression,” Clin exp Immunol 28:1-18, 1977).
Bissery Marie-Christine
Chiron-Blondel Marielle
Demers Brigitte
Vrignaud Patricia
Aventis Pharma SA
Fetterolf Brandon J
Lin Jiang
LandOfFree
Combination comprising combretastatin and anticancer agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination comprising combretastatin and anticancer agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination comprising combretastatin and anticancer agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4165495